{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:10:23Z","timestamp":1785859823296,"version":"3.56.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["XXXXX"],"award-info":[{"award-number":["XXXXX"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>B cells are critical mediators of systemic lupus erythematosus (SLE) and lupus nephritis (LN), and antinuclear antibodies can be found in the serum of approximately 98% of patients with SLE. Spleen tyrosine kinase (SYK) is a nonreceptor tyrosine kinase that mediates signaling from immunoreceptors, including the B cell receptor. Active, phosphorylated SYK has been observed in tissues from patients with SLE or cutaneous lupus erythematosus, and its inhibition is hypothesized to ameliorate disease pathogenesis. We sought to evaluate the efficacy and characterize the mechanism of action of lanraplenib, a selective oral SYK inhibitor, in the New Zealand black\/white (NZB\/W) murine model of SLE and LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Lanraplenib was evaluated for inhibition of primary human B cell functions in vitro. Furthermore, the effect of SYK inhibition on ameliorating LN-like disease in vivo was determined by treating NZB\/W mice with lanraplenib, cyclophosphamide, or a vehicle control. Glomerulopathy and immunoglobulin G (IgG) deposition were quantified in kidneys. The concentration of proinflammatory cytokines was measured in serum. Splenocytes were analyzed by flow cytometry for B cell maturation and T cell memory maturation, and the presence of T follicular helper and dendritic cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In human B cells in vitro, lanraplenib inhibited B cell activating factor-mediated survival as well as activation, maturation, and immunoglobulin M production. Treatment of NZB\/W mice with lanraplenib improved overall survival, prevented the development of proteinuria, and reduced blood urea nitrogen concentrations. Kidney morphology was significantly preserved by treatment with lanraplenib as measured by glomerular diameter, protein cast severity, interstitial inflammation, vasculitis, and frequency of glomerular crescents; treatment with lanraplenib reduced glomerular IgG deposition. Mice treated with lanraplenib had reduced concentrations of serum proinflammatory cytokines. Lanraplenib blocked disease-driven B cell maturation and T cell memory maturation in the spleen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lanraplenib blocked the progression of LN-like disease in NZB\/W mice. Human in vitro and murine in vivo data suggest that lanraplenib may be efficacious in preventing disease progression in patients with LN at least in part by inhibiting B cell maturation. These data provide additional rationale for the use of lanraplenib in the treatment of SLE and LN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-021-00178-3","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T19:05:02Z","timestamp":1617044702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4076-0309","authenticated-orcid":false,"given":"Christopher W.","family":"Pohlmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hua","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid S.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard P.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Newstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. David","family":"Inzunza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska G.","family":"Matzkies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"178_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/ar3433","volume":"13","author":"T Dorner","year":"2011","unstructured":"Dorner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther. 2011;13:243.","journal-title":"Arthritis Res Ther"},{"key":"178_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.biocel.2009.10.011","volume":"42","author":"E Nashi","year":"2010","unstructured":"Nashi E, Wang Y, Diamond B. The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol. 2010;42:543\u201350.","journal-title":"Int J Biochem Cell Biol"},{"key":"178_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nrrheum.2010.68","volume":"6","author":"I Sanz","year":"2010","unstructured":"Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:326\u201337.","journal-title":"Nat Rev Rheumatol"},{"key":"178_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/cmi.2012.64","volume":"10","author":"VS Chan","year":"2013","unstructured":"Chan VS, Tsang HH, Tam RC, Lu L, Lau CS. B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol. 2013;10:133\u201342.","journal-title":"Cell Mol Immunol"},{"key":"178_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","volume":"61","author":"J Barnas","year":"2019","unstructured":"Barnas J, Looney R, Anolik J. B cell targeted therapies in autoimmune disease. Curr Opin Immunol. 2019;61:92\u20139.","journal-title":"Curr Opin Immunol"},{"key":"178_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12:825\u201335.","journal-title":"Clin J Am Soc Nephrol"},{"key":"178_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1759720X17690474","volume":"9","author":"S Guerreiro Castro","year":"2017","unstructured":"Guerreiro Castro S, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther Adv Musculoskelet Dis. 2017;9:75\u201385.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"178_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrrheum.2015.159","volume":"12","author":"A Davidson","year":"2016","unstructured":"Davidson A. What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol. 2016;12:143\u201353.","journal-title":"Nat Rev Rheumatol"},{"key":"178_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","volume":"35","author":"RL Geahlen","year":"2014","unstructured":"Geahlen RL. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci. 2014;35:414\u201322.","journal-title":"Trends Pharmacol Sci"},{"key":"178_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/378303a0","volume":"378","author":"AM Cheng","year":"1995","unstructured":"Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378:303\u20136.","journal-title":"Nature."},{"key":"178_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1073\/pnas.97.4.1713","volume":"97","author":"RJ Cornall","year":"2000","unstructured":"Cornall RJ, Cheng AM, Pawson T, Goodnow CC. Role of Syk in B-cell development and antigen-receptor signaling. Proc Natl Acad Sci U S A. 2000;97:1713\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"178_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/378298a0","volume":"378","author":"M Turner","year":"1995","unstructured":"Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378:298\u2013302.","journal-title":"Nature."},{"key":"178_CR13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1084\/jem.179.5.1725","volume":"179","author":"T Kurosaki","year":"1994","unstructured":"Kurosaki T, Takata M, Yamanashi Y, Inazu T, Taniguchi T, Yamamoto T, et al. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med. 1994;179:1725\u20139.","journal-title":"J Exp Med"},{"key":"178_CR14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/j.1460-2075.1994.tb06387.x","volume":"13","author":"M Takata","year":"1994","unstructured":"Takata M, Sabe H, Hata A, Inazu T, Homma Y, Nukada T, et al. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J. 1994;13:1341\u20139.","journal-title":"EMBO J"},{"key":"178_CR15","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.4049\/jimmunol.1500461","volume":"194","author":"JA Ackermann","year":"2015","unstructured":"Ackermann JA, Nys J, Schweighoffer E, McCleary S, Smithers N, Tybulewicz VL. Syk tyrosine kinase is critical for B cell antibody responses and memory B cell survival. J Immunol. 2015;194:4650\u20136.","journal-title":"J Immunol"},{"key":"178_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.immuni.2012.11.015","volume":"38","author":"E Schweighoffer","year":"2013","unstructured":"Schweighoffer E, Vanes L, Nys J, Cantrell D, McCleary S, Smithers N, et al. The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity. 2013;38:475\u201388.","journal-title":"Immunity."},{"key":"178_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.15252\/embj.201489732","volume":"34","author":"E Hobeika","year":"2015","unstructured":"Hobeika E, Levit-Zerdoun E, Anastasopoulou V, Pohlmeyer R, Altmeier S, Alsadeq A, et al. CD19 and BAFF-R can signal to promote B-cell survival in the absence of Syk. EMBO J. 2015;34:925\u201339.","journal-title":"EMBO J"},{"key":"178_CR18","doi-asserted-by":"publisher","first-page":"e0156063","DOI":"10.1371\/journal.pone.0156063","volume":"11","author":"B Aouar","year":"2016","unstructured":"Aouar B, Kovarova D, Letard S, Font-Haro A, Florentin J, Weber J, et al. Dual role of the tyrosine kinase syk in regulation of toll-like receptor signaling in plasmacytoid dendritic cells. PLoS One. 2016;11:e0156063.","journal-title":"PLoS One"},{"key":"178_CR19","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1007\/s00018-014-1806-x","volume":"72","author":"M Kremlitzka","year":"2015","unstructured":"Kremlitzka M, M\u00e1csik-Valent B, Erdei A. Syk is indispensable for CpG-induced activation and differentiation of human B cells. Cell Mol Life Sci. 2015;72:2223\u201336.","journal-title":"Cell Mol Life Sci"},{"key":"178_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3389\/fimmu.2017.00775","volume":"8","author":"AN Suthers","year":"2017","unstructured":"Suthers AN, Sarantopoulos S. TLR7\/TLR9- and B cell receptor-signaling crosstalk: promotion of potentially dangerous B cells. Front Immunol. 2017;8:775.","journal-title":"Front Immunol"},{"key":"178_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/ki.2015.29","volume":"88","author":"SP McAdoo","year":"2015","unstructured":"McAdoo SP, Bhangal G, Page T, Cook HT, Pusey CD, Tam FW. Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney Int. 2015;88:52\u201360.","journal-title":"Kidney Int"},{"key":"178_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/0961203314560424","volume":"24","author":"S Iwata","year":"2015","unstructured":"Iwata S, Yamaoka K, Niiro H, Jabbarzadeh-Tabrizi S, Wang SP, Kondo M, et al. Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus. Lupus. 2015;24:695\u2013704.","journal-title":"Lupus."},{"key":"178_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jaut.2015.01.009","volume":"58","author":"NH Chang","year":"2015","unstructured":"Chang NH, Li TT, Kim JJ, Landolt-Marticorena C, Fortin PR, Gladman DD, et al. Interferon-alpha induces altered transitional B cell signaling and function in systemic lupus erythematosus. J Autoimmun. 2015;58:100\u201310.","journal-title":"J Autoimmun"},{"key":"178_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/exd.12986","volume":"25","author":"C Braegelmann","year":"2016","unstructured":"Braegelmann C, H\u00f6lzel M, Ludbrook V, Dickson M, Turan N, Ferring-Schmitt S, et al. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. Exp Dermatol. 2016;25:375\u20139.","journal-title":"Exp Dermatol"},{"issue":"20","key":"178_CR25","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1021\/acs.jmedchem.8b00667","volume":"61","author":"MC Bryan","year":"2018","unstructured":"Bryan MC, Rajapaksa NS. Kinase inhibitors for the treatment of immunological disorders: recent advances. J Med Chem. 2018;61(20):9030\u201358.","journal-title":"J Med Chem"},{"key":"178_CR26","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/art.23428","volume":"58","author":"FR Bahjat","year":"2008","unstructured":"Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 2008;58:1433\u201344.","journal-title":"Arthritis Rheum"},{"key":"178_CR27","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/art.27534","volume":"62","author":"GM Deng","year":"2010","unstructured":"Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010;62:2086\u201392.","journal-title":"Arthritis Rheum"},{"key":"178_CR28","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1021\/jm500228a","volume":"57","author":"KS Currie","year":"2014","unstructured":"Currie KS, Kropf JE, Lee T, Blomgren P, Xu J, Zhao Z, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014;57:3856\u201373.","journal-title":"J Med Chem"},{"key":"178_CR29","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/annrheumdis-2014-205361","volume":"74","author":"PC Taylor","year":"2015","unstructured":"Taylor PC, Genovese MC, Greenwood M, Ho M, Nasonov E, Oemar B, et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2015;74:2123\u20139.","journal-title":"Ann Rheum Dis"},{"key":"178_CR30","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1002\/art.38851","volume":"66","author":"ME Weinblatt","year":"2014","unstructured":"Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2014;66:3255\u201364.","journal-title":"Arthritis Rheum"},{"key":"178_CR31","unstructured":"van Vollenhoven R, Cohen SB, Mease PJ, Peterfy CG, Spieler W, Boice J, et al. Efficacy and safety of MK-8457, a novel SYK inhibitor for the treatment of rheumatoid arthritis in two randomized, controlled, phase 2 studies. Poster presented at American College of Rheumatology Annual Meeting; November 14\u201319, 2014; Boston, MA. Abstract 1528."},{"key":"178_CR32","unstructured":"TAVALISSE\u2122 (fostamatinib disodium hexahydrate) Highlights of prescribing information. https:\/\/tavalisse.com\/downloads\/pdf\/Tavalisse-Full-Prescribing-Information.pdf. Accessed 12 February 2020."},{"key":"178_CR33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1021\/acsmedchemlett.9b00621","volume":"11","author":"SK Currie","year":"2020","unstructured":"Currie SK, Blomgren P, Chandrasekhar J, Di Paolo JA, Geng G, Ip C, et al. Discovery of lanraplenib (GS-9876): a once-daily spleen tyrosine kinase inhibitor for autoimmune diseases. ACS Med Chem Lett. 2020;11:506\u201313.","journal-title":"ACS Med Chem Lett"},{"key":"178_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1749-6632.1997.tb52046.x","volume":"815","author":"O Chan","year":"1997","unstructured":"Chan O, Madaio MP. Shlomchik. The roles of B cells in MRL\/lpr murine lupus. Ann N Y Acad Sci. 1997;815:75\u201387.","journal-title":"Ann N Y Acad Sci"},{"key":"178_CR35","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nri3487","volume":"13","author":"RC Rickert","year":"2013","unstructured":"Rickert RC. 2013. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013;13:578\u201391.","journal-title":"Nat Rev Immunol"},{"key":"178_CR36","doi-asserted-by":"publisher","first-page":"e000199","DOI":"10.1136\/lupus-2016-000199","volume":"5","author":"ML Richard","year":"2018","unstructured":"Richard ML, Gilkeson G. Mouse models of lupus: what they tell us and what they don't. Lupus Sci Med. 2018;5:e000199.","journal-title":"Lupus Sci Med"},{"key":"178_CR37","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/01.bor.0000135452.62800.8f","volume":"16","author":"AH Sawalha","year":"2004","unstructured":"Sawalha AH, Harley JB. Antinuclear autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol. 2004;16:534\u201340.","journal-title":"Curr Opin Rheumatol"},{"key":"178_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/art.1780230304","volume":"23","author":"E Scopelitis","year":"1980","unstructured":"Scopelitis E, Biundo JJ Jr, Alspaugh MA. Anti-SS-A antibody and other antinuclear antibodies in systemic lupus erythematosus. Arthritis Rheum. 1980;23:287\u201393.","journal-title":"Arthritis Rheum"},{"key":"178_CR39","first-page":"156","volume":"56","author":"DA Herrera-vanOostdam","year":"2004","unstructured":"Herrera-vanOostdam DA, Esparza-Ibarra E, Ram\u00edrez-Sandoval R, Ort\u00edz V, Bollain-y-Goitia JJ, Avalos-Diaz E, et al. Apoptosis and necrosis increase antigenicity of proteins recognized by antinuclear antibodies. Reumatismo. 2004;56:156\u201361.","journal-title":"Reumatismo."},{"key":"178_CR40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1297-319X(03)00019-8","volume":"70","author":"R Ram\u00edrez-Sandoval","year":"2003","unstructured":"Ram\u00edrez-Sandoval R, S\u00e1nchez-Rodr\u00edguez SH, Herrera-van Oostdam D, Avalos-D\u00edaz E, Herrera-Esparza R. Antinuclear antibodies recognize cellular autoantigens driven by apoptosis. Joint Bone Spine. 2003;70:187\u201394.","journal-title":"Joint Bone Spine"},{"key":"178_CR41","doi-asserted-by":"publisher","first-page":"9813","DOI":"10.1073\/pnas.0909927107","volume":"107","author":"A Hakkim","year":"2010","unstructured":"Hakkim A, F\u00fcrnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010;107:9813\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"178_CR42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0272-6386(12)80488-4","volume":"17","author":"LA Hebert","year":"1991","unstructured":"Hebert LA. The clearance of immune complexes from the circulation of man and other primates. Am J Kidney Dis. 1991;17:352\u201361.","journal-title":"Am J Kidney Dis"},{"key":"178_CR43","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/08916930701510673","volume":"40","author":"L Truedsson","year":"2007","unstructured":"Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40:560\u20136.","journal-title":"Autoimmunity."},{"key":"178_CR44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.autrev.2008.06.002","volume":"8","author":"M Kavai","year":"2008","unstructured":"Kavai M. Immune complex clearance by complement receptor type 1 in SLE. Autoimmun Rev. 2008;8:160\u20134.","journal-title":"Autoimmun Rev"},{"key":"178_CR45","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/art.1780400803","volume":"40","author":"J Craft","year":"1997","unstructured":"Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum. 1997;40:1374\u201382.","journal-title":"Arthritis Rheum"},{"key":"178_CR46","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.cell.2017.07.026","volume":"170","author":"SE Degn","year":"2017","unstructured":"Degn SE, van der Poel CE, Firl DJ, Ayoglu B, Al Qureshah FA, Bajic G, et al. Clonal evolution of autoreactive germinal centers. Cell. 2017;170:913\u201326 e19.","journal-title":"Cell"},{"key":"178_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/1529-0131(200102)44:2<368::AID-ANR55>3.0.CO;2-6","volume":"44","author":"EL Greidinger","year":"2001","unstructured":"Greidinger EL, Hoffman RW. The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B'\/B proteins as predominant U1 RNP immunogens. Arthritis Rheum. 2001;44:368\u201375.","journal-title":"Arthritis Rheum"},{"key":"178_CR48","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/art.10263","volume":"46","author":"F Monneaux","year":"2002","unstructured":"Monneaux F, Muller S. Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum. 2002;46:1430\u20138.","journal-title":"Arthritis Rheum"},{"key":"178_CR49","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","volume":"41","author":"JM Dal Porto","year":"2004","unstructured":"Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol. 2004;41:599\u2013613.","journal-title":"Mol Immunol"},{"key":"178_CR50","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1006\/jmbi.1998.1964","volume":"281","author":"K F\u00fctterer","year":"1998","unstructured":"F\u00fctterer K, Wong J, Grucza RA, Chan AC, Waksman G. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol. 1998;281:523\u201337.","journal-title":"J Mol Biol"},{"key":"178_CR51","doi-asserted-by":"publisher","first-page":"11590","DOI":"10.1074\/jbc.270.19.11590","volume":"270","author":"RB Rowley","year":"1995","unstructured":"Rowley RB, Burkhardt AL, Chao HG, Matsueda GR, Bolen JB. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha\/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem. 1995;270:11590\u20134.","journal-title":"J Biol Chem"},{"key":"178_CR52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0167-4889(96)00131-0","volume":"1355","author":"MT Furlong","year":"1997","unstructured":"Furlong MT, Mahrenholz AM, Kim KH, Ashendel CL, Harrison ML, Geahlen RL. Identification of the major sites of autophosphorylation of the murine protein-tyrosine kinase Syk. Biochim Biophys Acta. 1997;1355:177\u201390.","journal-title":"Biochim Biophys Acta"},{"key":"178_CR53","doi-asserted-by":"publisher","first-page":"14846","DOI":"10.1016\/S0021-9258(18)98549-2","volume":"266","author":"JE Hutchcroft","year":"1991","unstructured":"Hutchcroft JE, Harrison ML, Geahlen RL. B lymphocyte activation is accompanied by phosphorylation of a 72-kDa protein-tyrosine kinase. J Biol Chem. 1991;266:14846\u20139.","journal-title":"J Biol Chem"},{"key":"178_CR54","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.4049\/jimmunol.161.10.5276","volume":"161","author":"LM Keshvara","year":"1998","unstructured":"Keshvara LM, Isaacson CC, Yankee TM, Sarac R, Harrison ML, Geahlen RL. Syk- and Lyn-dependent phosphorylation of Syk on multiple tyrosines following B cell activation includes a site that negatively regulates signaling. J Immunol. 1998;161:5276\u201383.","journal-title":"J Immunol"},{"key":"178_CR55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1074-7613(00)80591-9","volume":"9","author":"C Fu","year":"1998","unstructured":"Fu C, Turck CW, Kurosaki T, Chan AC. BLNK: a central linker protein in B cell activation. Immunity. 1998;9:93\u2013103.","journal-title":"Immunity."},{"key":"178_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nri1750","volume":"6","author":"GA Koretzky","year":"2006","unstructured":"Koretzky GA, Abtahian F, Silverman MA. SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond. Nat Rev Immunol. 2006;6:67\u201378.","journal-title":"Nat Rev Immunol"},{"key":"178_CR57","doi-asserted-by":"publisher","first-page":"32662","DOI":"10.1074\/jbc.274.46.32662","volume":"274","author":"LO Beitz","year":"1999","unstructured":"Beitz LO, Fruman DA, Kurosaki T, Cantley LC, Scharenberg AM. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem. 1999;274:32662\u20136.","journal-title":"J Biol Chem"},{"key":"178_CR58","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1074\/jbc.M407805200","volume":"280","author":"KD Moon","year":"2005","unstructured":"Moon KD, Post CB, Durden DL, Zhou Q, De P, Harrison ML, et al. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem. 2005;280:1543\u201351.","journal-title":"J Biol Chem"},{"key":"178_CR59","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1073\/pnas.92.2.359","volume":"92","author":"SP Sidorenko","year":"1995","unstructured":"Sidorenko SP, Law CL, Chandran KA, Clark EA. Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53\/56Lyn and a 120-kDa phosphoprotein. Proc Natl Acad Sci U S A. 1995;92:359\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"178_CR60","doi-asserted-by":"publisher","first-page":"11806","DOI":"10.1074\/jbc.270.20.11806","volume":"270","author":"AL Sillman","year":"1995","unstructured":"Sillman AL, Monroe JG. Association of p72syk with the src homology-2 (SH2) domains of PLC gamma 1 in B lymphocytes. J Biol Chem. 1995;270:11806\u201311.","journal-title":"J Biol Chem"},{"key":"178_CR61","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1074-7613(00)80273-3","volume":"5","author":"M Deckert","year":"1996","unstructured":"Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A. Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product. Immunity. 1996;5:591\u2013604.","journal-title":"Immunity."},{"key":"178_CR62","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/88756","volume":"2","author":"K Tedford","year":"2001","unstructured":"Tedford K, Nitschke L, Girkontaite I, Charlesworth A, Chan G, Sakk V, et al. Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. Nat Immunol. 2001;2:548\u201355.","journal-title":"Nat Immunol"},{"key":"178_CR63","doi-asserted-by":"publisher","first-page":"33760","DOI":"10.1074\/jbc.M704846200","volume":"282","author":"H Oh","year":"2007","unstructured":"Oh H, Ozkirimli E, Shah K, Harrison ML, Geahlen RL. Generation of an analog-sensitive Syk tyrosine kinase for the study of signaling dynamics from the B cell antigen receptor. J Biol Chem. 2007;282:33760\u20138.","journal-title":"J Biol Chem"},{"key":"178_CR64","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/ni1407","volume":"7","author":"A M\u00f3csai","year":"2006","unstructured":"M\u00f3csai A, Abram CL, Jakus Z, Hu Y, Lanier LL, Lowell CA. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat Immunol. 2006;7:1326\u201333.","journal-title":"Nat Immunol"},{"key":"178_CR65","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1074-7613(02)00420-X","volume":"17","author":"A Urzainqui","year":"2002","unstructured":"Urzainqui A, Serrador JM, Viedma F, Y\u00e1\u00f1ez-M\u00f3 M, Rodr\u00edguez A, Corb\u00ed AL, et al. ITAM-based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL-1. Immunity. 2002;17:401\u201312.","journal-title":"Immunity."},{"key":"178_CR66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.it.2006.12.004","volume":"28","author":"DM Underhill","year":"2007","unstructured":"Underhill DM, Goodridge HS. The many faces of ITAMs. Trends Immunol. 2007;28:66\u201373.","journal-title":"Trends Immunol"},{"key":"178_CR67","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bbamcr.2009.03.004","volume":"1793","author":"RL Geahlen","year":"2009","unstructured":"Geahlen RL. 2009. Syk and pTyr\u2019d: signaling through the B cell antigen receptor. Biochim Biophys Acta. 2009;1793:1115\u201327.","journal-title":"Biochim Biophys Acta"},{"key":"178_CR68","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/35642","volume":"391","author":"LL Lanier","year":"1998","unstructured":"Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 1998;391:703\u20137.","journal-title":"Nature."},{"key":"178_CR69","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0165-2478(96)02667-3","volume":"54","author":"Z Rozsnyay","year":"1996","unstructured":"Rozsnyay Z, Sarmay G, Zoller M, Gergely J. Membrane-bound ezrin is involved in B-cell receptor-mediated signaling: potential role of an ITAM-like ezrin motif. Immunol Lett. 1996;54:163\u20139.","journal-title":"Immunol Lett"},{"key":"178_CR70","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000345943","volume":"5","author":"J Rossaint","year":"2013","unstructured":"Rossaint J, Zarbock A. Tissue-specific neutrophil recruitment into the lung, liver, and kidney. J Innate Immun. 2013;5:348\u201357.","journal-title":"J Innate Immun"},{"key":"178_CR71","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.immuni.2007.04.011","volume":"26","author":"A Zarbock","year":"2007","unstructured":"Zarbock A, Lowell CA, Ley K. Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta (2) integrin-mediated rolling on intercellular adhesion molecule-1. Immunity. 2007;26:773\u201383.","journal-title":"Immunity."},{"key":"178_CR72","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1371\/journal.pone.0001132","volume":"2","author":"J Schymeinsky","year":"2007","unstructured":"Schymeinsky J, Then C, Sindrilaru A, Gerstl R, Jakus Z, Tybulewicz VL, et al. Syk-mediated translocation of PI3Kdelta to the leading edge controls lamellipodium formation and migration of leukocytes. PLoS One. 2007;2:e1132.","journal-title":"PLoS One"},{"key":"178_CR73","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/intimm\/dxf069","volume":"14","author":"SE Applequist","year":"2002","unstructured":"Applequist SE, Wallin RP, Ljunggren HG. Variable expression of toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol. 2002;14:1065\u201374.","journal-title":"Int Immunol"},{"key":"178_CR74","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.immuni.2010.03.012","volume":"32","author":"AL Blasius","year":"2010","unstructured":"Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity. 2010;32:305\u201315.","journal-title":"Immunity."},{"key":"178_CR75","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12026-012-8270-1","volume":"53","author":"T Celhar","year":"2012","unstructured":"Celhar T, Magalh\u00e3es R, Fairhurst AM. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res. 2012;53:58\u201377.","journal-title":"Immunol Res"},{"key":"178_CR76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2172-9-39","volume":"9","author":"JA Hanten","year":"2008","unstructured":"Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, et al. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol. 2008;9:39.","journal-title":"BMC Immunol"},{"key":"178_CR77","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/416603a","volume":"416","author":"EA Leadbetter","year":"2002","unstructured":"Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature. 2002;416:603\u20137.","journal-title":"Nature."},{"key":"178_CR78","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1074-7613(03)00323-6","volume":"19","author":"GA Viglianti","year":"2003","unstructured":"Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003;19:837\u201347.","journal-title":"Immunity."},{"key":"178_CR79","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13075-018-1702-0","volume":"20","author":"K Hjorton","year":"2018","unstructured":"Hjorton K, Hagberg N, Israelsson E, Jinton L, Berggren O, Sandling JK, et al. DISSECT consortium. Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. Arthritis Res Ther. 2018;20:238.","journal-title":"Arthritis Res Ther"},{"key":"178_CR80","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/art.20254","volume":"50","author":"T L\u00f6vgren","year":"2004","unstructured":"L\u00f6vgren T, Eloranta ML, B\u00e5ve U, Alm GV, R\u00f6nnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50:1861\u201372.","journal-title":"Arthritis Rheum"},{"key":"178_CR81","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4049\/jimmunol.170.2.846","volume":"170","author":"C Sedlik","year":"2003","unstructured":"Sedlik C, Orbach D, Veron P, Schweighoffer E, Colucci F, Gamberale R, et al. A critical role for Syk protein tyrosine kinase in fc receptor-mediated antigen presentation and induction of dendritic cell maturation. J Immunol. 2003;170:846\u201352.","journal-title":"J Immunol"},{"key":"178_CR82","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.4049\/jimmunol.1700069","volume":"199","author":"ML Bettini","year":"2017","unstructured":"Bettini ML, Chou PC, Guy CS, Lee T, Vignali KM, Vignali DAA. Cutting edge: CD3 ITAM diversity is required for optimal TCR signaling and thymocyte development. J Immunol. 2017;199:1555\u201360.","journal-title":"J Immunol"},{"key":"178_CR83","doi-asserted-by":"publisher","first-page":"a002485","DOI":"10.1101\/cshperspect.a002485","volume":"2","author":"PE Love","year":"2010","unstructured":"Love PE, Hayes SM. ITAM-mediated signaling by the T-cell antigen receptor. Cold Spring Harb Perspect Biol. 2010;2:a002485.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"178_CR84","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2249.2011.04505.x","volume":"167","author":"AK Chauhan","year":"2012","unstructured":"Chauhan AK, Moore TL. 2012. Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4(+) T cells. Clin Exp Immunol. 2012;167:235\u201345.","journal-title":"Clin Exp Immunol"},{"key":"178_CR85","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/art.33375","volume":"64","author":"D Ghosh","year":"2012","unstructured":"Ghosh D, Kis-Toth K, Juang YT, Tsokos GC. CREMalpha suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells. Arthritis Rheum. 2012;64:799\u2013807.","journal-title":"Arthritis Rheum"},{"key":"178_CR86","doi-asserted-by":"publisher","first-page":"e74550","DOI":"10.1371\/journal.pone.0074550","volume":"8","author":"AP Grammatikos","year":"2013","unstructured":"Grammatikos AP, Ghosh D, Devlin A, Kyttaris VC, Tsokos GC. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling. PLoS One. 2013;8:e74550.","journal-title":"PLoS One"},{"key":"178_CR87","doi-asserted-by":"publisher","first-page":"8145","DOI":"10.4049\/jimmunol.181.11.8145","volume":"181","author":"S Krishnan","year":"2008","unstructured":"Krishnan S, Juang YT, Chowdhury B, Magilavy A, Fisher CU, Nguyen H, et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol. 2008;181:8145\u201352.","journal-title":"J Immunol"},{"key":"178_CR88","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3389\/fimmu.2018.02169","volume":"9","author":"JK Krishnaswamy","year":"2018","unstructured":"Krishnaswamy JK, Als\u00e9n S, Yrlid U, Eisenbarth SC, Williams A. Determination of T follicular helper cell fate by dendritic cells. Front Immunol. 2018;9:2169.","journal-title":"Front Immunol"},{"key":"178_CR89","doi-asserted-by":"crossref","unstructured":"Krishnaswamy JK, Gowthaman U, Zhang B, Mattsson J, Szeponik L, Liu D, et al. Migratory CD11b(+) conventional dendritic cells induce T follicular helper cell-dependent antibody responses. Sci Immunol. 2017;2. pii: eaam9169.","DOI":"10.1126\/sciimmunol.aam9169"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-021-00178-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s41927-021-00178-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-021-00178-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T06:04:23Z","timestamp":1698127463000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-021-00178-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["178"],"URL":"https:\/\/doi.org\/10.1186\/s41927-021-00178-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-16421\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16421\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16421\/v1","asserted-by":"object"}]},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"27 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<i>Human sample collection.<\/i>Prior to blood collection, all individuals gave written informed consent in compliance with the Institutional Review Board-approved protocols for STEMCELL\u2122 Technologies (Vancouver, BC) or AllCells\u00ae (Alameda, CA).<i>Animal study.<\/i>This basic study design and animal usage was approved by Bolder BioPATH\u2019s Institutional Animal Care and Use Committee (IACUC) for compliance with regulations prior to study initiation (IACUC Protocol #BBP-005).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Gilead Sciences, Inc. CWP and CS hold stock in and receive research funding from the company. CS, ASC, RMJ, DAL, DWN, FGM, KSC, and JAD hold stock in the company. ZHC, BPM, and MDI declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}